Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling

The activation of AMPA receptors and mTOR signaling has been reported as mechanisms underlying the antidepressant effects of fast-acting agents, specially the NMDA receptor antagonist ketamine. In the present study, oral administration of agmatine (0.1 mg/kg), a neuromodulator that has been reported to modulate NMDA receptors, caused a significant reduction in the immobility time of mice submitted to the tail suspension test (TST), an effect prevented by the administration of DNQX (AMPA receptor antagonist, 2.5 mu g/site, i.c.v.), BDNF antibody (1 mu g/site, i.c.v.), K-252a (TrkB receptor antagonist, 1 mu g/site, i.c.v.), LY294002 (PI3K inhibitor, 10 nmol/site, i.c.v.) or rapamycin (selective mTOR inhibitor, 0.2 nmol/site, i.c.v.). Moreover, the administration of lithium chloride (non-selective GSK-3 beta inhibitor, 10 mg/kg, p. o.) or AR-A014418 (selective GSK-3 beta inhibitor, 0.01 mu g/site, i.c.v.) in combination with a sub effective dose of agmatine (0.0001 mg/kg, p.o.) reduced the immobility time in the TST when compared with either drug alone. Furthermore, increased immunocontents of BDNF, PSD-95 and GluA1 were found in the prefrontal cortex of mice just 1 h after agmatine administration. These results indicate that the antidepressant-like effect of agmatine in the TST may be dependent on the activation of AMPA and TrkB receptors, PI3K and mTOR signaling as well as inhibition of GSK-3 beta, and increase in synaptic proteins. The results contribute to elucidate the complex signaling pathways involved in the antidepressant effect of agmatine and reinforce the pivotal role of these molecular targets for antidepressant responses. (C) 2016 Elsevier B.V. and ECNP. All rights reserved.